Poor transfection efficiency is the major drawback of lipofection. We showed previously that addition of transferrin (TF) to Lipofectin enhanced the expression of a reporter gene in HeLa cells by 120-fold and achieved close to 100% transfection efficiency. The purpose of this study was to determine whether TF and other ligands could improve the efficiency of lipofection in lung carcinoma cells. Confluent A549, Calu3, and H292 cells were transfected for 18 hours with a plasmid DNA (pCMVlacZ) using Lipofectin plus TF, insulin, or epidermal growth factor as the vector. The transfected cells were assessed for transfection efficiency by ␤-galactosidase activity (light units/g protein) and the percentage of blue cells following 5-bromo-4-chloro-3-indolyl ␤-Dgalactopyranoside staining. Lipofectin supplemented with epidermal growth factor yielded the largest enhancement of lipofection efficiency (Յ23-fold over that by Lipofectin alone) in all three cell lines. Insulin significantly enhanced the lipofection efficiency in A549 and Calu3 cells but not in H292 cells, whereas TF showed significant lipofection efficiency-enhancing effect in Calu3 and H292 cells but not in A549 cells. The transfection efficiency correlated well with the amounts of DNA delivered to the nucleus as well as the amounts of the receptor. These results indicate that the gene delivery strategy employing ligand-facilitated lipofection can achieve high transfection efficiency in human lung carcinoma cells. In addition, enhancement of the expression of the receptor may be a possible strategy for increasing the efficiency of gene targeting. Cancer Gene Therapy (2000) 7, 59 -65
L ung cancer is one of the most frequently diagnosed malignant neoplasms throughout the world. 1 It is the leading cause of deaths for all cancer patients. 2 Despite much advancement in many therapeutic strategies, including surgery, chemotherapy, and radiation, life expectancy for patients with lung cancer has not been improved. Therefore, there is an urgent need to develop new therapy strategies for treating lung cancer. Gene therapy represents such a strategy.
The two major somatic gene transfer approaches employ viral [3] [4] [5] or nonviral vectors. 6, 7 Viral vectors have been shown to be efficient in delivering DNA to cells in vitro and in vivo. However, they are deficient in several areas. For example, adenoviral vectors induce a host immune response, rendering these vectors ineffective in repeated applications. 8, 9 Some viral vectors could cause random integration of viral DNA into the host genome, 3, 5, 10, 11 which poses a potential risk of neoplastic transformation. 4, 12 Adenoassociated virus prefers cells in the S phase to stationary phase for efficient transduction. 13 Furthermore, adenoassociated viral vector requires a high multiplicity of infection for infection, but it is difficult to prepare this vector in high titer. These drawbacks have limited the usage of this virus as a routine gene therapy vector. Alternatively, nonviral vectors provide promising alternatives to viral vectors. The two major classes of nonviral vectors include molecular conjugates of ligands with polylysine 14, 15 or histone, 15 cationic liposomes. 16, 17 Liposomes may be employed alone 18, 19 or as covalent 16, 17, 20 or noncovalent [21] [22] [23] [24] [25] complexes with a ligand. Compared with viral vectors, nonviral vectors are easy to prepare and store. They can deliver different kinds and lengths of DNA/RNA. However, gene delivery employing these nonviral vectors suffers from low transfection efficiency compared with viral vectors. If the transfection efficiency can be improved, nonviral vectors would have a great potential of becoming the vectors of choice for gene therapy.
Recently, we showed that supplementing cationic liposome with transferrin (TF) greatly enhanced the transfection efficiency in many cell lines, including HeLa cells 22 and human tracheal epithelial cells. 23 Employing this novel gene transfer strategy to deliver wild-type p53 gene, Xu et al 24 could sensitize a head and neck squamous carcinoma to radiation. In addition to high transfection efficiency, this vector can be readily prepared, because all the components needed for the construction of the vector are available commercially. In this study, we show that the ligand used for enhancing the transfection efficiency of lipofection is not limited to TF. Both epidermal growth factor (EGF) and insulin (INS) can enhance lipofection efficiency, suggesting that this gene transfer strategy is universally applicable to many different ligands and cells, including several human lung carcinomas.
MATERIALS AND METHODS

Materials
EGF, TF, and INS were purchased from Collaborative Research Products (Bedford, Mass). Lumi-Gal 530 for measuring ␤-galactosidase (␤-gal) activity was purchased from Lumigen (Southfield, Mich). Lipofectin was purchased from Life Technologies (Gaithersburg, Md). The monoclonal antibody against EGF receptor (EGFR) (Ab-3) was purchased from Oncogene Research Products (Cambridge, Mass). The protease inhibitor cocktail for mammalian cell and tissue extract and phenylmethylsulfonyl fluoride were purchased from Sigma (St. Louis, Mo).
Cell lines
Three human non-small cell lung cancer cell lines (A549, Calu3, and H292) used for the study were purchased from the American Type Culture Collection (Manassas, Va). They were maintained at 37°C in a 5% CO 2 /95% air atmosphere in F-12K nutrient mixture (Life Technologies), minimum essential medium (Life Technologies), and RPMI 1640 (Life Technologies) supplemented with 10% fetal bovine serum (Life Technologies), respectively.
Gene transfer protocol
Gene transfer was performed as described previously. 22 Cells that had grown to confluence in a 48-well culture plate were rinsed three times with 500 L of HEPES-buffered saline (HBS) (20 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES) (pH 7.2) containing 100 mM NaCl). These cells were then exposed to 500 L of the transfection solution that had been prepared as described below. In 12 ϫ 75-mm polystyrene tubes (Becton Dickinson, Lincoln Park, NJ), the following reagents were sequentially added, gently mixed, and subsequently incubated for 15 minutes at room temperature after each addition: 100 L of HBS containing freshly prepared EGF (2.5 g), INS (15 g), or TF (30 g); 3 L of Lipofectin (1 mg/mL); and 100 L of HBS containing 1.5 g of pCMVlacZ. The mixture was transferred to each well, which contained 300 L of serum-free medium without antibiotics, and was gently mixed. The plate was incubated for 18 hours at 37°C under a water-saturated environment and 5% CO 2 . The corresponding cultures exposed to Lipofectin plus DNA served as a control. Cells exposed to DNA only were another control. The conditioned media were then replaced with 1.0 mL of medium containing 10% fetal bovine serum and antibiotics (50 U/mL penicillin and 50 g/mL streptomycin). After culture for 48 hours, cells in three wells were fixed in 500 L of ice-cold 2% paraformaldehyde-0.2% glutaraldehyde for 10 minutes following removal of the conditioned medium and washing once with phosphate-buffered saline (PBS). The cells were then exposed to 0.5 mL of 1.0 mg/mL of 5-bromo-4-chloro-3-indolyl ␤-D-galactopyranoside (X-Gal) (Life Technologies) at 37°C for 2 days after the fixative had been removed and rinsed twice with PBS. The percentage of blue cells was measured by counting the number of blue cells out of a total of 2500 -3000 cells in 20 -30 randomly chosen fields under a phase-contrast microscope. Cells in three other wells were rinsed three times with PBS, dissociated by trypsinization, rinsed three times with PBS, and subsequently lysed by three cycles of freezing and thawing. These lysates were measured for ␤-gal activity as light units on a Labsystems Luminoscan (Boston, Mass) and for protein by the Bradford method (Bio-Rad, Melville, NY) using bovine serum albumin as the standard. Data were expressed as light units per microgram of protein.
Transfer of 32 P-labeled pCMVlacZ to lung cancer cells [ 32 P]pCMVlacZ was prepared using the Nick Translation System (Promega, Madison, Wis) and isolated on a microSpin G-25 column (Pharmacia Biotech, Piscataway, NJ). The radiolabeled product showed only one major band, which comigrated with pCMVlacZ on 1% agarose gel electrophoresis. The four different transfection solutions used for this experiment were: (a) DNA plus Lipofectin (6 g/mL), (b) EGF (5 g/mL) plus Lipofectin plus DNA, (c) INS (30 g/mL) plus Lipofectin plus DNA, and (d) TF (60 g/mL) plus Lipofectin plus DNA. The cultured cells in each well of a 12-well plate were exposed to 2 mL of the transfection solution containing 1.0 ϫ 10 6 counts per minute (cpm) of [ 32 P]pCMVlacZ. At 3 hours after transfection, the transfection media were removed; the amounts of DNA in the cells and in the nuclei were determined as follows: Transfected cells were washed twice with PBS, scraped with a rubber policeman, and collected in a 1.5-mL centrifuge tube. The cells were pelleted at 500 ϫ g for 5 minutes and washed once with PBS. The supernatant was removed and discarded. The pelleted cells were suspended in 500 L of Nonidet P-40 lysis buffer A (10 mM tris(hydroxymethyl)aminomethane-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl 2 , and 0.5% (vol/vol) of Nonidet P-40) and incubated for 5 minutes on ice. The cells were centrifuged for 5 minutes at 500 ϫ g, and the supernatant was saved. The pellet was washed twice with 500 L of lysis buffer A, and all of the supernatants were combined and measured for radioactivity, which was referred to as the cytoplasmic fraction. Next, the nuclear pellet was resuspended in 100 L of distilled water and measured for radioactivity, which was referred to as the nuclear fraction. The total cellular DNA was the summation of the radioactivity in the nuclear and cytoplasmic fractions. Data were expressed as cpm/well for both cellular and nuclear fractions.
Measurement of EGFR
Cellular proteins were radiolabeled by exposing cells to 100 Ci/mL of [ 35 S]methionine (Ͼ1000 Ci/mmol) (Amersham, Arlington Heights, Ill) according to the procedure described in the manual provided by the supplier of the monoclonal antibody (Oncogene Research Products). The cell monolayer that had been treated with [
35 S]methionine was washed three times with PBS. Cells were lysed on ice in 6 mL of lysis solution (10 mL of 100% Triton X-100, 5 g of sodium deoxycholate, 1.0 g of sodium dodecyl sulfate (SDS), a cocktail of protease inhibitors, 1 mM ethylenediaminetetraacetic acid, and 0.2 mM phenylmethylsulfonyl fluoride in 1 liter of PBS) for 20 minutes. Cell debris was removed by centrifugation at 2236 ϫ g at 4°C for 5 minutes. The remaining extract was initially treated with mouse nonimmune immunoglobulin (Sigma) and agaroseconjugated protein G (Oncogene Research Products). Next, the treated radiolabeled lysate was incubated with monoclonal antibody against EGFR for 24 hours at 4°C with mild agitation. The immunoprecipitate was then washed four times at 4°C with lysis buffer and separated by electrophoresis in a 6% polyacrylamide-SDS gel standardized with prestained high molecular mass markers (Bio-Rad Laboratories, Hercules, Calif). After being dried under vacuum at 70°C, the gel was analyzed using a PhosphorImager and ImageQuant software (Molecular Dynamics, Sunnyvale, Calif).
Other methods
pCMVlacZ was purified from Escherichia coli, which harbors this plasmid DNA, using a Qiagen plasmid isolation kit (Chatsworth, Calif).
Statistical analysis
Statistical analysis was performed using an unpaired Student's t test program (StatView, Abacus Concepts, Calabasas, Calif).
RESULTS
Effects of EGF, INS, and TF on the transfection efficiency of liposome-mediated gene transfer
The effects of EGF, INS, and TF on the transfection efficiency of lipofection were determined in three human lung carcinoma cell lines: A549, Calu3, and H292. As shown in Table 1 Figure 1 shows the representative results of X-Gal staining of these lung carcinoma cells transfected with pCMVlacZ by EGFfacilitated lipofection.
Our previous report showed that effective transfection complexes can be generated by sequential addition of Lipofectin, TF, and pCMVlacZ. 22 The data shown in Table 2 confirmed that this formulation strategy (i.e., addition of DNA last) also held true for other ligands, such as INS and EGF. When DNA was not added last, no enhancement of lipofection efficiency was observed.
Relationship between transfection efficiency and the amounts of DNA delivered to cells and nuclei To examine whether the enhancement of lipofection efficiency by each of these three ligands can be explained by helping to deliver more DNA to the cells and nuclei, we measured the amounts of 32 P-labeled pCMVlacZ in the cells and the nuclei following transfection of these cells with radiolabeled DNA. As shown in Figure 2A , supplementing Lipofectin with EGF increased the amounts of DNA delivered to A549 cells by 12-fold. INS and TF increased the amounts of DNA delivered to these cells by 4.6-and 2.6-fold, respectively. The amounts of DNA delivered to the nuclei of A549 cells with Lipofectin supplemented with EGF, INS, and TF were 14, 7.5, and 3 times that seen with Lipofectin alone, respectively (Fig 2B) . In Calu3 cells, EGF, INS, and TF enhanced the amounts of DNA delivered to the cells by Lipofectin by 7-, 4-, and 5-fold, respectively (Fig 3A) . Similarly, EGF, INS, and TF increased the amounts of DNA delivered by Lipofectin to Calu3 cells by 7-, 3-, and 4-fold, respectively (Fig 3B) . In H292 cells, the amounts of DNA delivered to these cells by Lipofectin supplemented with EGF, INS, and TF were 5.5, 1.6, and 2.6 times that seen for Lipofectin alone, respectively ( Fig  4A) . The amounts of DNA delivered to the nuclei of these cells by Lipofectin supplemented with EGF, INS, and TF were 11.5, 4.0, and 8.0 times that seen for Lipofectin alone, respectively (Fig 4B) .
Relationship between enhancement of lipofection efficiency by EGF and levels of EGFR in A549, Calu3, and H292 cells To assess whether the enhancement of lipofection efficiency by a ligand is related to the levels of the receptor present in these cells, we measured the relative amounts of EGFR in A549, Calu3, and H292 cells by Phos- Figure 5 , a prominent protein band with a molecular mass of ϳ170 kDa, which corresponds to the size of EGFR, 26 was identified. The relative amounts of EGFR in A549, Calu3, and H292 cells were estimated to be 5, 1, 7, respectively. The relative amounts of EGFR in these three cell lines correlate well with the relative enhancement of lipofection efficiency by EGF.
DISCUSSION
This report extends our previous observation 22 that supplementation of a cationic liposome (e.g., Lipofectin) with a ligand (e.g., TF) greatly enhances the transfection efficiency of lipofection. In this report, we show that in addition to TF, INS and EGF can enhance the transfection efficiency of lipofection. Because this gene-targeting strategy can apply to different cationic liposomes 22 and different ligands, a cell-specific gene-targeting vector that yields high transfection efficiency may be constructed from a wide variety of cationic liposomes and cell type-specific ligands. There is great potential for this gene-targeting strategy.
The vector formulation for ligand-facilitated lipofection gene transfer strategy that we developed previously 22 requires the addition of DNA last. This report confirms that when INS, TF, or EGF is used as the ligand, the formulation sequence needs to be followed to achieve enhancement of lipofection efficiency by the ligand (Table 2) . Although many ligands can enhance lipofection efficiency, the degree of enhancement varies with different ligands for each cell line (Table 1) . For each of these three human lung carcinoma cell lines, the degree of enhancement of the lipofection efficiency by these ligands correlates well with the amounts of DNA delivered to the cell and the nucleus (Figs 2-4) . These results indicate that the amount of DNA delivered to the cell, especially to the nucleus, is an important determinant of transfection efficiency. This result is not surprising, because transcription takes place in the nucleus of the cell. The more the plasmid DNA is delivered to the nucleus, the more the expression of the transgene would be expected. Our gene transfer strategy delivers more DNA to the nucleus than by liposome alone. Therefore, increased nuclear targeting of the therapeutic gene should be an important goal in the development of a high efficiency gene therapy strategy. Because many steps are involved in the delivery of the transgene to the nucleus, it would be important to identify which of the following steps are primarily responsible for increased delivery of DNA to the nucleus when liposome is supplemented with a ligand: binding of the transfection complex with EGFR, endocytosis of the EGFR-bound transfection complex, escape of DNA from the endosome, and transfer of DNA from the cytoplasm to the nucleus. Understanding the step(s) responsible for increasing nuclear targeting of the transgene should help us to further improve the efficiency of gene delivery by this gene-targeting strategy. Among the three ligands examined, EGF yields the largest enhancement of transfection efficiency in all three of the lung carcinomas tested. EGFR is known to be overexpressed in many tumor cells, including lung carcinomas. 27, 28 Attempts have been made by several laboratories to deliver DNA using vectors that target EGFR. In one report, anti-EGFR antibodies were conjugated with polylysine to deliver a reporter gene by taking advantage of the ability of polylysine to package DNA and anti-EGFR antibodies to bind to EGFR. 29 Chloramphenicol acetyltransferase was expressed in the cells transfected with plasmid DNA containing this reporter gene as mediated by the antibody-polylysine conjugate but not in the cells treated with DNA alone (i.e., without the conjugate). In another report, EGF was conjugated with a replication-defective adenovirus that used the ability of adenovirus to replicate intracellularly and EGF to seek out its abundant receptor on the surface of lung adenocarcinomas. 30 Very high transfection efficiency was observed for the strategy employing these adenoviral vectors. Also, EGF has been covalently conjugated with a cationic liposome to deliver a reporter gene to cancer cells. 16 This conjugate elicited significant transfection efficiency in cells expressing EGFRs but not in cells without EGFRs, suggesting an EGFR-mediated process. Addition of free EGF 16 or EGF plus INS 17 to . At 3 hours after transfection, cells were trypsinized, washed twice, and lysed in 500 L of Nonidet P-40 lysis buffer. Nuclei were pelleted at 500 ϫ g for 5 minutes, washed twice, resuspended in distilled water, and measured for radioactivity. The combined radioactivity recovered in the "nucleus" fraction and supernatants plus washings was designated as "cell." Data were expressed as cpm/well (mean Ϯ SEM) (n ϭ 3). Student's unpaired t test was employed to perform a statistical analysis of the significance of the difference in means between ligand-facilitated samples and control samples. 16 and Hara et al 17 compared with the overall enhancement of the lipofection efficiency (Յ23-fold) by EGF of our EGF-facilitated lipofection strategy, we believe that the bulk of the enhancement of the lipofection efficiency with our gene transfer strategy is attributed to receptor targeting rather than to the growth-stimulating properties of the ligand. This conclusion was supported by the observation that the lipofection efficiency in A549 cells was not enhanced when the normal sequence of vector formulation was modified ( Table 2 ). This result reproduces our previous finding in HeLa cells. 22 Nevertheless, our report confirms the feasibility of performing gene delivery by targeting EGFR. However, our gene-targeting strategy differs from these approaches in several areas. First, the EGF used in our gene delivery strategy is not conjugated to either liposome or DNA. The transfection vector is a noncovalent complex of Lipofectin, EGF, and DNA as generated by sequential addition of these three components according to the protocol described previously. 22 The way that the transfection vector is formulated is the unique feature of our gene delivery strategy, because the transfection complexes are formed noncovalently. Second, it has been documented that molecular conjugates 31 and adenoviral vectors 9 induced a host immune response to the vectors; this renders these two vectors useless when applied in vivo, because the transient expression nature of the transgenes delivered by these vectors requires repeated applications of the transgenes to maintain efficacy. On the contrary, the ligand used in our strategy is a natural compound that can be isolated from the same animal species in which gene therapy is to be performed. Host inflammatory or immune response to this ligand is not expected to occur. Recent results of the toxicity study of liposomes following their delivery to the lungs of human 32 and animals 33, 34 showed minimal to no host inflammatory response. Therefore, we do not anticipate significant adverse immunological or inflammatory response to our transfection vector when applied in vivo.
Although it has been reported that EGFR is overexpressed in lung carcinomas, 27, 28 our results show that the expression of this receptor varies with different lung carcinomas (Fig 5) . EGFR is expressed to approximately the same extent in A549 and H292 cells, which is much higher than the expression seen in Calu3 cells. It should be noted that the transfection efficiency of EGF-facilitated lipofection in our study parallels the relative expression of EGFRs in these three cell lines. These results suggest that the initial gene transfer steps (i.e., binding of the transfection complex and subsequent endocytosis) play pivotal roles in the transfection efficiency of EGF-facilitated lipofection. Enhancing the expression of the receptor would be one possible strat- S]methionine and lysed in 1% Nonidet P-40. EGFR was immunoprecipitated and separated by SDS-polyacrylamide gel electrophoresis (6% gel). The gel was calibrated with prestained high molecular mass markers that included myosin (200 kDa), ␤-gal (113 kDa), and bovine serum albumin (82 kDa), as indicated. The dehydrated gel was analyzed using a PhosphorImager. The band indicated by an arrow has a molecular mass of 170 kDa, which corresponds to the size of the EGFR.
egy to improve the efficiency of the ligand-facilitated lipofection gene therapy strategy.
